Skip to main content
Premium Trial:

Request an Annual Quote

GATC Biotech, Complete Genomics Ink Sequencing Pact

NEW YORK (GenomeWeb News) – GATC Biotech and Complete Genomics said today that they are collaborating to sequence several human genomes from samples provided by GATC.

Under the agreement, Mountain View, Calif.-based Complete Genomics will sequence and assemble the genomes and provide GATC with detected variants including single nucleotide polymorphisms and indels.

GATC, based in Konstanz, Germany, will then perform bioinformatics analyses such as comparing the variant data of different genomes; and will refine the data with the intent of providing researchers and clinicians with relevant genomic details to advance their understanding of the genetic causes of diseases.

"To achieve our 100-Human-Genome-Project goal, evaluating Complete Genomics' human genome sequencing technology is a logical step," Peter Pohl, CEO of GATC Biotech, said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.